ELEV Company Profile and Key Details

Elevation Oncology, Inc. has 59.22 million shares outstanding. The public float is 43.51 million shares, elevated short interest at 7.48% of float. This equals 3.62 million shares. The short ratio is 3.1 days. Institutional investors hold 59.94% of the float. Insiders own 0.36%. Aisling Capital IV, LP holds 2.83 million shares, Qiming U.S. Healthcare Fund II, L.P. has 2.37 million shares and Vertex Global HC Fund II Pte. Ltd. has 2.31 million shares.

ELEV has shown weak momentum, losing -3.87% over the past week and -3.46% over the past quarter, though year-to-date performance is down -35.12%. Short-term trend indicators are mixed aligned (SMA20 -3.08%, SMA50 3.02%, SMA200 -25.38%). The stock’s 14-day RSI is 45.79 (neutral), while the ATR of 0.01 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -88.19% below its high and over 65.16% above its low.

Elevation Oncology, Inc. generated EPS of -$0.81 over the past year. Five-year average earnings growth is -25.69%. Wall Street analysts project EPS growth of 19.08% annually over the next five years. The latest quarter delivered EPS of -$0.18. The next quarter is forecast at -$0.18. Next year's EPS is expected at $19.22. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $0.70. The high target offers 1844.44% upside. The low target suggests 94.44% downside. The mean target is $2.94. This offers 716.67% upside. Elevation Oncology, Inc. earnings surprise history is a mixed track record. The quarter that ended August 05, 2025, missed forecasts by -30.77%. The prior quarter beat by 20.0%. Over the last six quarters, Apple has recorded several small beats. These include 9.52% in May 02, 2024.

Elevation Oncology, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.32. This means the shares are trading above this model’s fair value.

Elevation Oncology, Inc. (NASDAQ:ELEV) closed at $0.36 USD, losing -$0.01 (-2.12%) from the previous close of $0.37. The stock is currently mid-range between its 52-week high and low $0.22 and $3.09. With a market capitalization of about $21.63 million, Elevation Oncology, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.50). Key stats such as the average daily volume over the past year has been around 1.35 million shares, trading with heavier-than-usual volume. Headquartered in Boston, NY, Elevation Oncology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Joseph J. Ferra Jr., the company employs approximately 34 people and listed since June 25, 2021. Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States.

Elevation Oncology, Inc. (NASDAQ:ELEV) shares are down -35.12% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Elevation Oncology, Inc. trading at a premium to the broader market with a P/E of -0.58. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $5.43, suggesting 1387.67% upside. Our AI forecast model points to short-term weakness (-4.11% over two weeks), a medium-term fall (-61.64% over three months), and a longer-term loss (-58.9% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Elevation Oncology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.11%, with price expected at $0.35 by August 14, 2025, within a range of $0.35 to $0.36 3-Month Outlook: Projected fall of -61.64%, reaching $0.14 by October 29, 2025, with a range of $0.05 to $0.23. 1-Year Outlook: Projected loss of -58.9%, with price at $0.15 by July 31, 2026, within a range of $0.00 to $0.00.

Elevation Oncology, Inc. trades at a P/E ratio of -0.58, slightly below the S&P 500 average, with a price-to-sales ratio of 569.14 and a price-to-book ratio of 0.46 suggesting the stock is closer to book value. The P/FCF stands at -0.69, also below market averages.